ArticleThe Journal of infectious diseases2025
Strength and Durability of Respiratory Syncytial Virus Prefusion F Immunoglobulin G Following Infection and Exposure in a Household Cohort, 2014-2022.
Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Diagnostic performance and interchangeability of two commercial anti-RSV-IgG and IgA ELISAs across clinically relevant populations.Microbiology spectrum · 2026Article
- Trajectories and determinants of respiratory syncytial virus prefusion F-specific IgG in older adults.BMC infectious diseases · 2026Article
- Serological evidence of substantial respiratory syncytial virus infection burden among older adults residing in Swedish long-term care facilities.BMC medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundLittle is known about the strength and durability of protection provided by prefusion F (pre-F) immunoglobulin G (IgG) after respiratory syncytial virus (RSV) infection/exposure.
methodsWe analyzed 1019 sera from 422 individuals in 173 households, collected 365 days before and after RSV infection or exposure (2014-2022), from a longitudinal cohort with active respiratory infection surveillance. IgG against RSV pre-F was measured by electrochemiluminescence assay. We used a Cox model, adjusted for age, to assess the association between log4 preinfection/exposure IgG and risk of infection. We compared pre- and postinfection/exposure IgG geometric mean concentration increases among cases and household contacts to identify asymptomatic infections. Generalized additive mixed models predicted IgG concentrations over time.
resultsWe identified 113 confirmed RSV cases and 377 exposed household contacts. Cases had significantly lower pre-F IgG before infection (P < .05) and significantly higher levels after infection (P < .05). A 1-unit increase in log4 preinfection IgG decreased the risk of infection by 25% (P < .05). Among 58 cases with pre- to post-RSV geometric mean concentration increases, the mean fold increase was 1.12. Eight individuals without confirmed infections had ≥1.12-fold increases and were classified as probable asymptomatic infections. Cases had the highest IgG concentrations after infection, peaking at 1 month (P < .001).
conclusionsPre-F IgG is a reliable correlate of protection for RSV infection risk. We found that RSV pre-F IgG-mediated protection starts to wane 6 months after infection. Therefore, scheduling of RSV vaccination should be evaluated so that individuals with the highest risk of severe disease are protected throughout the RSV season.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.